Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Oct;32(10):e70078.
doi: 10.1111/jvh.70078.

Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-Analysis

Jing Xiao  1 , Xinnian Zhang  1 , Xiaozhou Mao  1 , Shunhao Lai  1 , Shuangli Li  1 , Yunjian Sheng  1
Affiliations
Meta-Analysis

Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-Analysis

Jing Xiao et al. J Viral Hepat. 2025 Oct.

Abstract

To assess the efficacy and safety of the Velpatasvir (VEL)/Sofosbuvir (SOF) with or without Ribavirin (RBV) in treating patients with decompensated hepatitis C cirrhosis. We searched multiple databases for studies published from October 2010 to September 2024. Outcomes of interest were sustained viral response at 12 weeks (SVR12) and the safety of VEL/SOF with and without RBV regimens in patients with decompensated hepatitis C virus (HCV) cirrhosis. All statistical analyses were performed using R Statistics (4.4.1). We included 13 studies that enrolled 872 adult patients with decompensated cirrhosis due to HCV. The addition of RBV to the VEL/SOF regimen neither significantly improved SVR12 after the last dose of treatment [95.0% (366/391, 95% CI: 89.0-99.0) vs. 94.0% (442/481, 95% CI: 90.0-97.0); p = 0.92] nor decreased virologic relapse [1.0% (2/158, 95% CI: 0.0-8.0) vs. 6.0% (12/197, 95% CI: 3.0-10.0); p = 0.15]. VEL/SOF plus RBV therapy had a significantly higher rate of adverse events [92.0% (261/287, 95% CI: 88.0-95.0) vs. 47.0% (167/348, 95% CI: 24.0-71.0); p < 0.01] and death [7.0% (20/287, 95% CI: 2.0-16.0) vs. 2.0% (8/366, 95% CI: 1.0-4.0); p = 0.05]. However, for patients with genotype 3, adding RBV to the VEL/SOF regimen significantly improved SVR12 [87.0% (26/30, 95% CI: 71.0-98.0) vs. 45% (7/15, 95% CI: 13.0-79.0); p < 0.01] and decreased virologic relapse [0.0% (0/10, 95% CI: 0.0-31.0) vs. 100% (1/1, 95% CI: 2.0-100.0); p = 0.02]. VEL/SOF based therapy is a safe and effective treatment for patients with decompensated cirrhosis due to HCV. The addition of RBV to VEL/SOF may increase toxicity without achieving improved efficacy overall. However, the addition of RBV significantly increased the SVR12 rate and reduced the virologic relapse in genotype 3 patients. Trial Registration: PROSPERO database: CRD42023491852.

Keywords: decompensated hepatitis C cirrhosis; meta‐analysis; ribavirin; sofosbuvir; velpatasvir.

PubMed Disclaimer

References

    1. S. Blach, S. Zeuzem, M. Manns, et al., “Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modelling Study,” Lancet Gastroenterology & Hepatology 2, no. 3 (2017): 161–176.
    1. J. P. Messina, I. Humphreys, A. Flaxman, et al., “Global Distribution and Prevalence of Hepatitis C Virus Genotypes,” Hepatology 61, no. 1 (2015): 77–87.
    1. M. Kamal‐Yanni, “Hepatitis C Drug Affordability,” Lancet Global Health 3, no. 2 (2015): e73–e74.
    1. X. Wang, X. Fan, H. Deng, et al., “Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Virus Genotypes 1‐6 Infection: A Systematic Review and Meta‐Analysis,” International Journal of Antimicrobial Agents 54, no. 6 (2019): 780–789.
    1. M. Dugum and R. O'Shea, “Hepatitis C Virus: Here Comes All‐Oral Treatment,” Cleveland Clinic Journal of Medicine 81, no. 3 (2014): 159–172.

MeSH terms

LinkOut - more resources